Gyre pivots to China commercial pharma; launches Etorel and Contiva, raises cash, revenue dips

Gyre Therapeutics, Inc. (NASDAQ: CBIO) - Quick read on what's happening inside

Short version: the company is transitioning from legacy Catalyst operations into a China-focused commercial biopharma (Gyre Pharmaceuticals). It launched two new products in 2025 (Contiva in March, Etorel in June), raised capital in May, and shows positive operating cash flow in H1 2025 - but revenue for the first half fell year-over-year and operating costs (especially G&A) increased materially. Significant noncontrolling interest and customer concentration in China are key governance/operational realities.

Key facts & figures (as reported)
- Revenues: Q2 2025 $26,771,000 vs Q2 2024 $25,225,000; Six months 2025 $48,829,000 vs six months 2024 $52,397,000.
- Gross profit: Q2 2025 $25,620,000 (gross margin ≈95.7%); six months 2025 $46,784,000 (≈95.8%).
- Operating expenses (Q2 2025): Total operating expenses $24,600,000; Selling & marketing $15,194,000; R&D $3,425,000; G&A $4,829,000.
- Income from operations: Q2 2025 $2,171,000 (Q2 2024 $3,194,000). Six months 2025 $4,444,000 (six months 2024 $11,265,000).
- Net income (consolidated): Q2 2025 $1,576,000 vs Q2 2024 $4,538,000. Six months 2025 $5,310,000 vs $14,473,000.
- Net income attributable to common stockholders: Q2 2025 $442,000; six months 2025 $3,140,000.
- EPS (basic): Q2 2025 $0.00; six months 2025 $0.04. Diluted six months 2025 $0.01.
- Cash & liquidity (June 30, 2025): Cash & cash equivalents $36,491,000; short-term bank deposits $17,874,000; long‑term certificates of deposit $21,528,000. Total reported financial assets ≈ $68,047,000.
- Balance sheet snapshot (June 30, 2025): Total assets $152,646,000; Total liabilities $23,203,000; Total equity $129,443,000. Accumulated deficit $70,313,000.
- Shares outstanding: 90,822,828 shares as of June 30, 2025.
- Noncontrolling interest: $37,417,000 (significant minority holders in consolidated results).
- Recent financing: May 2025 underwritten offering - issued 2,555,555 shares; gross proceeds ~$23,000,000 (net proceeds ~ $21.3M after fees). ATM sales also provided $509,000 in H1 2025.
- Warrant liability (Level 3): $3,201,000 at June 30, 2025 (down from $5,668,000 at Dec 31, 2024). CVR derivative liability fully settled as of June 30, 2025.
- Intangibles: Technology rights (Etorel) recognized ~$4.9M (RMB 35.0M) and amortization began; intangible assets, net $4,962,000 (up from $273,000 at Dec 31, 2024).
- Accounts & receivables: Accounts receivable, net $24,629,000; one customer (Sinopharm) ~52.9% of AR and ~53.3% of revenue in Q2 2025 (Sinopharm + Shanghai Pharma + China Resources = ~79% of revenue).
- Inventory increased to $8,861,000 (June 30, 2025) from $6,337,000 (Dec 31, 2024).

Positives (income statement and related)
- High gross margins (~96%) on product sales - product business is highly profitable at gross margin level.
- Revenue growth quarter-over-quarter for Q2 (Q2 2025 > Q2 2024) driven by new product launches (Etorel, Contiva).
- Company returned to positive net income in H1 2025 ($5.31M) and generated net cash from operations ($1.96M) in the six months ended June 30, 2025.
- Strong cash raise in May 2025 (~$23M gross) materially improved liquidity (cash increased from $11.8M to $36.5M).
- Investment in product portfolio: Etorel technology rights recognized and commercialized in June 2025 - diversifies revenue beyond ETUARY®.

Negatives / risks (income statement and business)
- Six-month revenue fell Y/Y: $48.8M (H1 2025) vs $52.4M (H1 2024) driven by a $6.8M decline in ETUARY® sales despite new-product gains; short-term top-line pressure remains.
- Operating profitability compressed: income from operations dropped (Q2 and H1) versus prior year; G&A rose sharply (G&A +41% Q/Q, +43% Y/Y for six months) - higher overhead and stock-based comp are weighing on margins.
- Large allocation to noncontrolling interest: a material portion of consolidated net income is attributable to noncontrolling interests (e.g., Q2 noncontrolling interest $1.134M of total $1.576M net income).
- Customer concentration: Sinopharm alone accounted for ~53% of Q2 revenue and ~53% of AR - single-customer dependency is high.
- Market & FX exposure: 100% of product sales are PRC-based; RMB controls and foreign exchange limitations and PRC healthcare spending weakness pose revenue and repatriation constraints (restricted capital noted ~$64.7M).
- Share dilution & stock-based comp: large option pool and unrecognized stock-comp expense ($14.7M unrecognized) and potential dilution from outstanding options/warrants (diluted share counts >100M).
- Volatility in non-operating items: change in fair value of warrant liability materially moves reported earnings (H1 2024 and 2025 swings). Warrant remeasurements reduced "other income" vs prior year, lowering reported profits.

What to watch next
- Commercial traction for Etorel and Contiva (monthly/quarterly sales trends) - management expects these to offset ETUARY® declines.
- Hydronidone regulatory pathway: NMPA NDA planned Q3 2025; IND filing in U.S. planned Q3 2025 and potential U.S. Phase 2 start H2 2025 - trial progress and approvals are value drivers.
- Customer diversification (reduce dependency on Sinopharm) and working capital collection trends (AR concentration).
- G&A and stock-comp run-rate - whether G&A growth moderates as new product launches normalize.
- Cash runway after H1 2025 raise - current cash and deposits (~$68.0M total cash-equivalents and deposits) vs operating burn including planned R&D (Hydronidone, F573, others).

Bottom line: Gyre (NASDAQ: CBIO) is executing a product-driven strategy in China with early success from two 2025 launches and has materially strengthened liquidity via a May equity raise. However, H1 revenue was down year-over-year, operating costs (especially G&A) are rising, and the business relies heavily on a few Chinese distributors/customers and has significant noncontrolling interests. Monitor product sales momentum, Hydronidone regulatory progress, and whether operating expense growth slows.

Sources: Gyre Therapeutics, Inc. Form 10-Q for quarter ended June 30, 2025 (figures and text above drawn directly from the filing).